Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company") (NASDAQ: OSIR) concerning possible violations of federal securities laws.

On May 27, 2016, Osiris disclosed in an SEC filing that it is the subject of a criminal investigation by the U.S. Attorney's Office for the Southern District of New York. According to Osiris, this investigation concerns matters similar to those already under investigation by the SEC. Osiris has repeatedly delayed the filing of its Form 10-Q for the quarter ended March 31, 2016 as it undergoes an accounting review and audit of certain previous financial statements. In addition, the Company is currently the subject of a lawsuit filed by competitor MiMedx Group, Inc. According to the complaint, Osiris allegedly released false and misleading clinical data concerning one of its drug treatments. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/osiris-therapeutics-osir

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160601006335/en/

Copyright Business Wire 2010